Experimental cancer drug trial halted early
Disease control
Terminated
This study tested a new oral drug called TNG908 in adults with advanced solid tumors that lack the MTAP gene. The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 03, 2026 15:07 UTC